Performance 
significantly 
second 
half 
weighted, as 
anticipated, with 
strong 
execution of backlog, resulting in positive 
Group REBIT of EUR 6.4 million (FY22 EUR 
11.1 million)

Very 
strong 
Other 
Accelerators 
and 
Dosimetry REBIT driven by high value 
backlog conversion and sales growth, compensating 
Proton 
Therapy 
REBIT

=== Page 50 ===
IBA Annual Report 2023 
47. IBA 
affected by customer delays, inflationary 
pressures and R&D investments